Yannis K. Valtis, MD
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
Conditions I Treat
- Leukemia
My Specialties
- Cellular therapy
Get to Know Me
I am a medical oncologist who has special training in the treatment of leukemia and other blood cancers. I have a special interest and experience in the use of cellular therapy for the treatment of these cancers. Cellular therapy aims to use the patient’s own immune cells to treat the cancer. This can help reduce the amount of chemotherapy a patient receives and prevent related side effects to the body.
I see patients at Memorial Sloan Kettering (MSK) Westchester and the David H. Koch Center for Cancer Care at MSK.
I strive to get to know every patient and their family and craft a treatment plan that honors their values and wishes. My goal is for patients to leave every visit feeling like their questions were answered and have a deep understanding of their care plan.
My research focuses on clinical trials which aim to test novel treatments for the care of patients with leukemia and other blood cancers. I also have an interest in using large datasets to understand why treatments succeed or fail and how we can improve them.
I’m a leukemia specialist, which is a doctor with special training in diagnosing and treating leukemia (loo-KEE-mee-uh). This cancer starts in tissue that forms blood, such as bone marrow.
A cellular therapy specialist is a doctor with special training in using cell therapies to treat health conditions such as cancer. Therapies can include chimeric antigen receptor (CAR) T cell therapy.
- Assistant Attending Physician
Conditions I Treat
- Leukemia
My Specialties
- Cellular therapy
Education
- BA, Harvard College
- MD, Harvard Medical School
Residencies
- Internal Medicine and Pediatrics, Brigham and Women's Hospital/Boston Children's Hospital
Fellowships
- Hematology and Oncology, Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine, Medical Oncology
Awards and Honors
- Young Investigator Award, Conquer Cancer Foundation (2024)
- Inaugural Acute Lymphoblastic Leukemia Young Investigator Forum Second Prize (2023)
- Abstract Achievement Award, American Society of Hematology (2024, 2023, 2020)
- Summa Cum Laude, Harvard College (2012)
- Phi Beta Kappa, Harvard College (2012)
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, EPO PPO, POS, Transplant
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO
This plan is in-network at our New York sites only.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
Supplemental
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
POS, HMO
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
HMO
This plan is in-network at our New York sites only.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
HMO
This plan is in-network at our New York sites only.
In Network Coverage Type
PPO
This is a dual payer plan, which means 2 health insurance companies share this plan. MSK providers are out-of-network with UnitedHealthcare.
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
HMO
This plan is in-network at our New York sites only.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
This plan is in-network at our New York sites only.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
PPO EPO
In Network Coverage Type
HMO
Your plan may not cover visits to our New York sites. Please call the number on the back of your insurance card to see what your health plan covers.
In Network Coverage Type
PPO
Your plan may not cover visits to our New York sites. Please call the number on the back of your insurance card to see what your health plan covers.
In Network Coverage Type
EPO
Your plan may not cover visits to our New York sites. Please call the number on the back of your insurance card to see what your health plan covers.
In Network Coverage Type
EPO
Your plan may not cover visits to our New York sites. Please call the number on the back of your insurance card to see what your health plan covers.
In Network Coverage Type
PPO, HMO
Your plan may not cover visits to our New York sites. Please call the number on the back of your insurance card to see what your health plan covers.
In Network Coverage Type
State Government
This plan is in-network at our New York sites only.
In Network Coverage Type
PPO, POS, EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
HMO (City Employee Health Plans Gold and Gold Care Only)
In Network Coverage Type
Supplemental
In Network Coverage Type
PPO/OAP
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
TBD
In Network Coverage Type
PPO, EPO
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
State Government
This plan is in-network at our New York sites only.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO, POS
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
State Government
Learn more about the insurance plans that participate with MSK.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
Health plans can change at any time. Call the number on the back of your insurance card to see what your plan covers. Make sure it covers the MSK location where you’ll get care.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Valtis
- A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
1. Valtis YK, Devlin SM, Shouval R, Rejeski K, Corona M, Luna De Abia A, Rivas-Delgado A, Luttwak E, Cassanello G, Landego I Dr, Schöder H, Bedmutha A, Boardman AP, Shah GL, Scordo M, Perales MA, Salles GA, Palomba ML, Shah UA, Park JH. Cancer cachexia and weight loss prior to CAR T-cell therapy for lymphoma are independently associated with poor outcomes. Blood Adv. 2024 Oct 29.
2. Valtis YK, Nemirovsky D, Dekach A, Sharah S, Kabel C, Ortiz R, Thmpson M, Roeker L, Geyer MB. Real-world incidence and prevention of tumor lysis syndrome in chronic lymphocytic leukemia treated with venetoclax. Blood Advances. 2024 Aug 9.
3. Valtis YK, Flamand Y, Shimony S, Place AE, Silverman LB, Vrooman LM, Brunner AM, Sallan SE, Wadleigh M, Stone RM, DeAngelo DJ, Luskin MR. Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. Leukemia. 2024 Mar;38(3):482-490
Visit PubMed for a full listing of Dr. Valtis’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.
MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.
Yannis K. Valtis discloses the following relationships and financial interests:
-
Autolus Therapeutics
Professional Services and Activities -
EastRx
Professional Services and Activities
-
Valius Health Inc.
Equity; Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2025 through disclosure submission in spring 2026). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].